RICHARD R RAWLINGS

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology PHOENIX, AZ NPI 1700832508

General Payments — all program years on this page

$949.72

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 28
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $530.68 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $530.6819

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $71.801
2021 $68.893
2023 $278.355
2024 $530.6819

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1078865085 Actelion Pharmaceuticals US, Inc. $30.99 01/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865087 Actelion Pharmaceuticals US, Inc. $32.03 02/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865383 Actelion Pharmaceuticals US, Inc. $30.55 10/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865385 Actelion Pharmaceuticals US, Inc. $31.90 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865407 Actelion Pharmaceuticals US, Inc. $28.90 03/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865453 Actelion Pharmaceuticals US, Inc. $27.66 10/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865521 Actelion Pharmaceuticals US, Inc. $31.35 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865635 Actelion Pharmaceuticals US, Inc. $26.04 08/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865703 Actelion Pharmaceuticals US, Inc. $29.68 09/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865725 Actelion Pharmaceuticals US, Inc. $28.84 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865775 Actelion Pharmaceuticals US, Inc. $30.35 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865817 Actelion Pharmaceuticals US, Inc. $27.68 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078865891 Actelion Pharmaceuticals US, Inc. $31.64 05/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1080687360 ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $25.35 09/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105759093 AstraZeneca Pharmaceuticals LP $21.38 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114144247 Regeneron Healthcare Solutions, Inc. $19.25 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125208845 Abbott Laboratories $24.45 01/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125208847 Abbott Laboratories $24.67 07/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142112681 ARGENX US, INC. $27.97 07/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.